Purchase Order 75N95023P00549
Award Date 9/1/23
Potential Completion Date 10/31/23
Potential Value $64K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
China
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award was issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a global contract research organization. The $87,805.00 firm fixed price contract was awarded as a delivery order under the NIH Bioanalysis Testing Services 2015-2020 master contract vehicle. Under this contract, Pharmaron conducted various drug development activities for NCATS, including...
- This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...
- This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...
- This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The contract is valued at $24,320.00 and does not have a set-aside designation. The contract is for pharmacokinetic studies of two compounds in non-naive cynomolgus monkeys, using both oral and intravenous routes of administration, with bioanalyses in plasma conducted in triplicate. This...
- The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $108,000 purchase order to Pharmaron, Inc. for pharmacokinetics experiments involving forty rodents across two study arms. The one-year contract has Pharmaron performing the work in China under a firm fixed price arrangement. No additional details were provided on subcontractors or the specific NIH programs the research aims to support. The award information...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) awarded a firm fixed price purchase order contract valued at $10,440.00 to Pharmaron, Inc., a minority-owned, for-profit organization based in China. The contract is for a pharmacokinetic study of the drugs tamoxifen and neurotinib, with a period of performance running through October 9, 2023. Pharmaron has received over 30 prior prime contract awards...
- This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Pharmaron, Inc.'s Phamaron Inc. Division. The contract, valued at $23,040.00, is for a pharmacokinetics assessment of eight novel compounds in mice and rats. Pharmaron is a global contract research organization (CRO) that specializes in preclinical research services, including pharmacokinetics assessments, toxicity...
- This is a $35,600 firm fixed price purchase order contract awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct a mouse study evaluating NNMT inhibitors in high grade serous ovarian cancer. The work, which has a 12-month period of performance, involves formulating compounds, developing a mouse model, conducting efficacy studies, and analyzing samples. No set-aside...
- This firm fixed-price purchase order was awarded by the Department of Health and Human Services' (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct testing of compounds for the blocking of cardiac ion channels. The period of performance is from August 7, 2020 to December 31, 2021, with a potential value of $24,795.00. The work is being performed in Louisville, Kentucky....
- The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services (HHS), has awarded a $124,200.00 firm fixed-price purchase order contract to Pharmaron, Inc., a minority-owned business based in China, to evaluate the pharmacokinetics of compounds from dystonia in mice, dogs, and rats. This sole-source contract, awarded under simplified acquisition procedures, will require Pharmaron to provide consistency and...